What is Symphogen?
Symphogen is a private biopharmaceutical firm at the forefront of developing innovative antibody mixtures for therapeutic applications, primarily targeting oncology and other critical diseases. The company's core mission is to bring optimally selected antibody mixtures as single drug products to market. Symphogen has established strategic collaborations, including one with Genentech for infectious disease therapeutics and another with Shire for immuno-oncology drug development. Founded in 2000 and headquartered in Denmark, Symphogen leverages its expertise to create next-generation antibody-based medicines.
How much funding has Symphogen raised?
Symphogen has raised a total of $188.9M across 2 funding rounds:
Private Equity
$112.3M
Debt
$76.6M
Private Equity (2011): $112.3M with participation from Essex Woodlands, Novo A/S, and Danish Pension Fund PKA
Debt (2015): $76.6M led by PKA and Novo A/S
Key Investors in Symphogen
Essex Woodlands
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns. The firm partners with experienced management teams in the pharmaceuticals, MedTech, and tech-enabled services sectors, providing capital and strategic guidance to accelerate business growth.
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
PKA
PKA is one of the largest pension service providers for labor market pension funds in Denmark, investing approximately DKK 275 billion (EUR 36.6 billion) on behalf of their members. PKA has a special focus on long term infrastructure investments and has invested approximately DKK 20 billion (EUR 2.7 billion) in Danish and foreign infrastructure.
What's next for Symphogen?
The significant enterprise-level backing and recent strategic investment position Symphogen for accelerated growth and the advancement of its therapeutic pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to expand its collaborative efforts and move its promising antibody mixture candidates through clinical trials. The company's focus on oncology and infectious diseases, coupled with its unique approach to antibody therapeutics, suggests a strategic expansion into key areas of unmet medical need.
See full Symphogen company page
